Healthcare Industry News: neuromodulation
News Release - March 8, 2010
Bioness Appoints New President and CEOVALENCIA, Calif.--(HSMN NewsFeed)--Bioness Inc. announces that its Board of Directors named Thomas G. Fogarty as the company’s new President and CEO, effective February 4th. Fogarty succeeds former President and CEO Yitzhak Zilberman, who has left the company.
“Under Yitzhak’s leadership, Bioness brought its core NESS functional electrical stimulation products to market and in doing so has helped countless individuals suffering with mobility issues,” said Alfred Mann, Chairman of the Board of Bioness.
Mann continued, “We are delighted that Tom Fogarty will now be leading Bioness as the company moves to a new phase. Tom brings deep industry experience and a proven track record of developing cutting edge technology, optimizing operational efficiencies and driving revenue growth in medical device companies. His insights into the successful commercialization of medical devices will be an integral part of Bioness’ strategy going forward.”
Mr. Fogarty is a 25 year veteran of the medical device industry, having held various senior management positions at public and private companies, including Johnson & Johnson, Medtronic, Baxter, Edwards Lifesciences, and ev3. He assisted in the development and global commercialization of more than 25 products over the course of his career. Mr. Fogarty has also helped lead the sale of an early-stage device company to a publicly traded company.
Mr. Fogarty most recently held the position of President of Incumed, LLC, a holding company that oversees a portfolio of early-stage companies for Alfred Mann. Within that framework, Mr. Fogarty was the operating President of four early-stage device companies, focused on pain management, drug delivery, tinnitus and location/tracking devices. Mr. Fogarty currently sits on the board of three device companies and holds a BS from California Polytechnic University and an MBA from Pepperdine University.
“I am honored by the opportunity to join Bioness and look forward to leading the company through its next stage of growth,” said Fogarty. “The company’s commitment to providing individuals with new levels of physical independence and its talented and passionate team is truly a winning combination.”
About Bioness Inc.
Bioness offers innovative neuromodulation products designed to help certain individuals with central nervous system disorders and diseases such as Stroke, Multiple Sclerosis, Traumatic Brain Injury, Cerebral Palsy and Spinal Cord Injury. These products use electrical stimulation to help people regain mobility, physical independence and productivity.
The NESS L300™ Foot Drop System and NESS H200® Hand Rehabilitation System, cleared for use by the Food and Drug Administration and CE-marked for the European Union.
Individual results vary. Consult with a qualified physician to find out if these products are right for you.
Additional information about Bioness can be found at www.bioness.com.
NESS®, NESS H200®, NESS L300™, Intelli-Gait™, Intelli-Sense Gait Sensor™, Bioness®, the Bioness Logo, LiveOn™ and For function. For freedom. For life.™ are trademarks of Bioness Inc. | www.bioness.com | Rx Only
Use of the symbols ® and ™ herein refers to the registration status of trademarks in the U.S. only. These trademarks may also be registered in other countries.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.